News
Public · Published
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics' Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
SRX Global announced that the University of California, Davis has been activated as a clinical trial site for CERo Therapeutics' ongoing Phase 1 CERTAIN-T trial of CER-1236 in patients with hematologic malignancies. UC Davis is also the primary manufacturing site for CER-1236.
Published:
Updated:
What happened
SRX Global announced that the University of California, Davis has been activated as a clinical trial site for CERo Therapeutics' ongoing Phase 1 CERTAIN-T trial of CER-1236 in patients with hematologic malignancies. UC Davis is also the primary manufacturing site for CER-1236.
Confirmed
Global impact / market context
Adding a site that already makes CER-1236 could speed patient recruitment and simplify treatment logistics, which may help the trial progress faster. SRX agreed to acquire CERo, so operational progress at CERo can affect the value investors place on that deal.
Analyst inference
The news follows SRX's definitive agreement to acquire CERo, a cellular immunotherapy company developing engineered T cell therapies that engage phagocytic mechanisms, which means helping immune cells engulf targets. It suggests the acquisition target is still advancing its clinical program while the deal is pending.
Analyst inference
What to watch
- UC Davis is the primary manufacturing site for CER-1236, so its activation combines trial enrollment with existing production capacity, which the company says is expected to streamline treatment logistics for patients. Confirmed
- Track enrollment updates from CERTAIN-T, a Phase 1 study testing safety and early activity in blood cancers, because patient numbers would show whether the new site actually expands recruitment capacity as expected. Proposed
- Watch progress toward closing SRX's previously announced acquisition of CERo, since delays or changes in the trial could shift how investors value CERo's main asset, CER-1236. Analyst inference